Eagle’s Eye View: Racial Differences in SGLT2i Treatments
Release Date:
In this week’s View, Dr. Eagle explores the association of successful percutaneous revascularization of chronic total occlusions with quality of life. He then discusses the feasibility and safety of flecainide use among patients with varying degrees of coronary disease. Finally, Dr. Eagle looks at an incredibly important meta-analysis on the racial differences in quality of life among patients with heart failure who are treated with sodium-glucose cotransporter 2 inhibitors. Subscribe to Eagle’s Eye View
Eagle’s Eye View: Racial Differences in SGLT2i Treatments